ASP per therapy. RESULTS: Annual net reimbursement revenues per patient based on 340B acquisition costs were projected to be $53,270 for dabrafenib+trametinib combination, $27,043 for vemurafenib, $22,634 for dabrafenib, and $19,029 for trametinib. CONCLUSIONS: The addition of user-modifiable projected reimbursement revenue calculation is a valuable tool that expands the contribution of economic modeling to hospital formulary decision-making.
OBJECTIVES:
Little is known about cancer (CA) in hospitalization, cost and outcomes in transitional countries. We studied this in a multicentric hospital study in Argentina. METHODS: Adult CA, hospital direct costs, re-admissions (ReH < 30 days) and deaths in 1 yr output of 3 academic hospitals. Cost and results, harmonized according HCUPS (USA) terminology groupers, of primary (1Dx), and secondary diagnosis (2Dx) for each CCS code (Clinical Classification Software-CCS single level-SL, 2009). Total costs (CT$), mean costs (SD) and median per discharge cost ($, 25P-75P-percentiles), in Itl.$ PPP, (UN Data: 1Arg$ = 1.608 PPP, 2008) . CA defined as (#CCS [descriptive term]), including from CCS #11 [head and neck CA] to #44 [Neoplasms of unspecified nature or uncertain behavior] and CCS 45 [Maintenance chemotherapy; radiotherapy--QT;RT]. Readmisions (ReH) < 30 days and hospital deaths were obtained. RESULTS: Among 45 466 ≥ 19 yrs.old, CA was found in 6 282, 13, 81%(95%CI 13, 14) Dx1; CCS 11-45 (F= 49,33%) (individual CA data not shown) while QT;RT (# 45) = 2 520 disch., 5,54% (4,75-5,15 ). Among CCS 45 [QT;RT] en 1Dx, CCS #11-44 in any 2Dx up to 5 2Dx code adds 3,046 disch; adding CA codes 1Dx +2Dx = 9.298 discharges (20,45%, 20,08-20,82) . Among CCS en 1Dx, CT $ = I $ PPP 64 088 727; mean: I$ 17,035; SD: I$ 4,276; median: I$ 8,897 (25P 4,042; 75 P 19,601) . ReH < 30 d = 485 (1,06 %, 0.97-1,16); while QT-RT (#45) ReH< 30 = 1,754 (3,86%, 3,68-4,04) . Case fatality rate for CCS 11-44 was 3,27%, (2, 74) , and for CCS 45 was 0,17%,( 0,06-0,45). CONCLUSIONS: CA burden among hospital discharges, and its costs, case fatality, and readmisions were obtained for the first time in Argentina. QT-RT as a first Dx is close to half of discharges, and showing CA en 2Dx behaves differently in ReH and mortality. An iceberg phenomenon of CA in 2Dx emerges.
PCN42 TreaTmeNT PaTTerNs aNd CosTs assoCiaTed WiTh sUNiTiNiB aNd PazoPaNiB TreaTmeNT for reNal Cell CarCiNoma: a CommerCial healTh Claims aNalysis
OBJECTIVES: Real-world data may inform decisions regarding treatment for renal cell carcinoma (RCC). We compared treatment persistence and healthcare costs for sunitinib and pazopanib, considering dosing cycle differences' effect on days supply. METHODS: This retrospective cohort study used the Truven Marketscan® database. Inclusion criteria were RCC diagnoses, age ≥ 20 years, ≥ 1 (index) prescription for sunitinib or pazopanib 10/1/2009 -9/30/2013, and continuous plan enrollment ≥ 6 months before to 12 months after index. We compared demographic and clinical characteristics and treatment patterns, using Chi-square, Student t-test, and Wilcoxon signed-rank test (α = 0.05). Costs were compared using generalized linear modeling to adjust for demographic, clinical, and medication variables. Sensitivity analysis assessed effects of imputing days supply for sunitinib's 42-day dosing for prescriptions with 28 or 30 days supply. RESULTS: Among 466 patients (77% receiving sunitinib), the cohorts were not significantly (NS) different in demographics or Charlson Comorbidity Index. More sunitinib patients (46 vs. 6 pazopanib patients; p= 0.038) had of public healthcare in Ecuador to predict the financial consequences of introducing axitinib as a second line treatment in Ecuador. METHODS: Using a budget Impact analysis model, we estimated the incremental impact in the Ministry of public healthcare budget in Ecuador with the introduction of axitinib as treatment for mRCC in whom have failed the first line treatment. The comparative used drugs were sorafenib, everolimus, sunitinib, pazopanib and bevacizumab + IFNa. The epidemiological data was taken from GLOBOCAN 2012. The costs information 2014 was obtained from public sources and the model was built in Microsoft Excel 2007. The economic analysis is based in the incidence of RCC: metastatic, non-metastatic and the percentage of the patients with progression. The model considers two scenarios: 1) The current market of treatment without Axitinib, 2) The current market adding Axitinib. RESULTS: Based on the incidence of RCC and the Ecuador population, we calculated 269 incident cases of RCC, 211 with metastatic disease and 58 who will progress to metastatic disease, 97 patients received a first line treatment of whom 40.91% (40 patients) needed a 2ndline treatment. Along a 3 year followup in the scenario were axitinib was added, the estimated cost was $5,810,416.84 USD, with an incremental change of $26,098.99 USD and an incremental cost for the population with access to the national healthcare system of $0.00010 USD p/ month. CONCLUSIONS: The addition of axitinib as a second line treatment for mRCC had a minimal impact on the budget designated to the Ministry of public healthcare in Ecuador, and since it has an A1 recommendation level, it will represent an improvement in the mRCC treatment options. OBJECTIVES: Prostate cancer is the second leading cause of cancer death in American men and has a high economic burden. Enzalutamide received FDA approval for an expanded indication based on significant improvement in overall survival and radiographic progression-free survival in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients. Our objective was to estimate the 1-year budget impact (BI) of adopting enzalutamide's expanded indication. METHODS: Epidemiologic data, including SEER incidence rates, were used to estimate total number of chemotherapy-naïve mCRPC patients in a hypothetical 1-million member U.S. health plan. Treatment options included abiraterone acetate, sipuleucel-T, radium-223 dichloride, and docetaxel. Dosing, administration, mean duration of therapy and adverse event (AE) rates were based on package inserts and pivotal studies. Drug costs (including pre-and concomitant medications) were obtained from RedBook and CMS ASP pricing files, administration and monitoring from CMS Physician Fee Schedule, and AEs from AHRQ H-CUP and published literature. Drug utilization was estimated for each comparator before and after adoption of enzalutamide. Incremental aggregate budget, per patient per year (PPPY), per patient per month (PPPM), and per member per month (PMPM) impact were calculated. One-way sensitivity analyses were performed. RESULTS: In an estimated population of 115 mCRPC patients, adopting the new enzalutamide indication had modest annual plan impact ($510,641 incremental aggregate BI, $4,426 PPPY, $368.83 PPPM and $0.04 PMPM). Enzalutamide acquisition cost was partially offset by moderate AEs and no additional monitoring costs. Results were most sensitive to enzalutamide drug cost, size of chemotherapy-naïve mCRPC patient population and enzalutamide adoption rate. CONCLUSIONS: Results indicate a modest 1-year BI to adopt enzalutamide for chemotherapy-naïve mCRPC patients, partly due to the cost offset of moderate incidence of AEs and lack of additional required monitoring. Further analysis to understand cost per clinical outcome may complement the BI model to understand relative costs and benefits. OBJECTIVES: Economic modeling is an accepted tool for making formulary decisions by payers in the US. Hospital and institutional healthcare providers have expressed increased interest in using economic modeling in their decision making processes, particularly regarding potential reimbursement based on hospital-specific pricing. This study presents hospital perspective results from a revenue impact (RI) calculator component of an economic model. METHODS: An economic model was developed that investigated the RI (pharmaceutical acquisition costs minus projected reimbursement) of introducing National Comprehensive Cancer Network Category 1 recommended therapies for BRAF V600 mutated metastatic melanoma to a hospital formulary. Therapies investigated in the analysis included: dabrafenib+trametinib combination therapy, vemurafenib monotherapy, dabrafenib monotherapy, and trametinib monotherapy. The model calculated the annual pharmaceutical acquisition cost of each therapy based on recommended dosing, progression-free survival as a marker for duration of treatment, and drug pricing. Pricing data was retrieved from the Truven Health Analytics RED BOOK™ database. Acquisition costs in the model could be set to 340B, wholesale acquisition cost (WAC), or average wholesale price (AWP) values. The model used a default 30% discount compared to WAC to approximate 340B pricing. The projected reimbursement in the model uses WAC plus a modifiable 4.3% (based on the Medicare permitted reimbursement premium) for both Medicare and commercial payers. The perspective payer mix and respective reimbursement percentages can be modified by the model user. WAC was used in place of average sales price (ASP) due to the unavailability of hospital-specific OBJECTIVES: To examine and compare costs and cost drivers for various metastatic renal cell carcinoma (mRCC) drugs. METHODS: This retrospective cohort study used administrative healthcare claims from MarketScan® Commercial and Medicare Supplemental Databases to identify patients newly diagnosed with mRCC (index event) from 1/1/2006 to 3/31/2014, with continuous health plan enrollment at least 6 months prior to and 30 days following the index date. Treatment with approved mRCC products on or after the index date was required. Patients were followed until death, health plan enrollment end, initiation of non-mRCC chemotherapy, or study end. Healthcare costs reflect paid amounts to providers and out-of-pocket costs to patients. Bootstrapping was used to determine differences between costs of drugs. RESULTS: The study population included 3060 mRCC patients. Total per-patient-per-month costs for pazopanib ($14,486) and sorafenib ($13,841) were not statistically lower at an alpha level of 0.05 than sunitinib ($15,808). However, temsirolimus ($19,431) and IL-2 ($96,619) were significantly more costly than sunitinib. For inpatient and patient out-ofpocket costs, IL-2 was significantly more costly than sunitinib. Outpatient costs of pazopanib and temsirolimus were both significantly more costly than sunitinib while sorafenib was significantly less costly. Multivariate modeling found that year of index date, number of metastatic sites, NCI comorbidity index score, and evidence of an adverse event during first line treatment were significantly associated with greater costs for all patients. In general, approximately 46% of total costs were specific to mRCC drug costs while 30% were due to inpatient stay. CONCLUSIONS: This study demonstrates that there may be significant cost differences between mRCC drugs and that mRCC drug costs represent the largest driver of total healthcare costs in this patient population. Further research on comparative effectiveness, weighing costs relative to clinical benefit, is needed.
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PCN46
ChoiCe of seqUeNTial BiologiCal TheraPies iN meTasTaTiC ColoreCTal CaNCer (mCrC): a CosT ComParisoN aNalysis for Wild-TyPe Kras mCrC PaTieNTs iN Brazil
Tsuchiya C. T. , Kim H. S. , La Scala C. S.
Roche Brazil, São Paulo, Brazil
OBJECTIVES: Colorectal cancer (CRC) is a major cause of morbidity and mortality worldwide. Approximately 25% of patients present metastatic disease at diagnosis and about 50% will develop metastatic disease. Patients with metastatic colorectal cancer (mCRC) and wild-type or mutated KRAS are eligible for sequential treatments, including monoclonal antibodies as first or second-line regimens. Use of bevacizumab (Bev) through multiple lines (TML) may benefit patients with mCRC. Considering the emerging data, it is important to understand these implications in terms of costs for the Brazilian private healthcare system. Our objectives were to compare economic outcomes of different sequences of therapy including monoclonal antibodies for the treatment of mCRC. METHODS: Eight scenarios were analyzed, each one comparing different treatment sequences. A sequence of bevacizumab TML (first-line and beyond first progression) was compared in each scenario with another sequence without bevacizumab TML. To compare the economic outcomes, the monthly cost and the total cost of the sequence per patient were calculated, according to the first, second and third-lines combinations. RESULTS: Considering a standard time of treatment of 12.8 months and progression-free survival (PFS) varying from 17.0 to 20.6, all scenarios with bevacizumab TML were less costly than multiple lines without bevacizumab. The lowest monthly cost was related to bevacizumab TML (1stline bevacizumab 5mg+FOLFOX → 2ndline bevacizumab 5mg+FOLFIRI → 3rdline best supportive care [BSC] ). This sequence represents a monthly cost of R$ 18,192.41 per patient while the same scenario with cetuximab in first-line (1stline cetuximab 250mg+FOLFIRI → 2ndline bevacizumab 10mg+FOLFOX → 3rdline BSC) represents R$ 23,640.57 per month/ patient. CONCLUSIONS: Use of bevacizumab TML for mCRC is less costly compared with sequences of biological therapy that starts with cetuximab in the first-line followed by bevacizumab in second-line treatment. Resource savings with sequential bevacizumab have the potential to optimize third-line treatment strategy for mCRC patients with wild-type KRAS in Brazil. OBJECTIVES: To investigate patterns of hemostat methods in surgeries and evaluate the healthcare resource utilization and economic burden of patients in China. METHODS: All Patients using oxidized regenerated cellulose (ORC), microfibrillar collagen hemostat (MCH), resorbable oxidized cellulose (ROC), and microporous polysaccharide hemispheres (MPH) after cholecystectomy, hysterectomy or other related surgeries in tertiary hospitals were identified from the 2012 dataset of the China Health Insurance Research Association (CHIRA) claims database which includes a nationwide, cross-sectional sampling of inpatients. Direct medical costs included diagnostic tests, surgery, physiotherapy, hemostat, medicines and consumables cost. Descriptive statistics were used to describe patient profiles, healthcare resource utilization and direct medical cost. Two-tailed tests were performed at 95% confidence. Multiple linear regression (MLR) was used to identify main parameters that may influence inpatient costs thus providing patient selection criteria for a relative unbiased comparison. RESULTS: A total of 788 patients with the following characteristics, age, gender, surgery types, hemostats types, Length of Stay (LOS), Hospital tier were identified. Factors significantly impacted inpatient cost were Length of Stay, type of hemostat (ORC vs. others), tier of Medical Institute (MLR, p< 0.01). Among 382 patients who stayed at Tier 3 hospitals with LOS ≤ 14 days, the average inpatient costs of patients using ORC vs. other hemostats (MCH, ROC, MPH) were 21,101 RMB (±21,390), 23,246 RMB (±15,545), respectively. There was a signifi-chronic pulmonary disease. The sunitinib cohort had less time between diagnosis and index prescription than the pazopanib cohort (334 vs. 422 days; p= 0.037). Proportions of patients with treatment continuation, discontinuation, switching, or interruption were NS different. Before imputation, adjusted mean [SD] daily medication costs during persistence were higher for sunitinib ($218.19 [34.73] vs. $177.07 [45.76] ; p< 0.0001), but NS different after imputation (sunitinib $181.41 [22.34] vs. pazopanib $175.77 [44.26] ; p= 0.213). Twelve-month adjusted RCC-related medical costs were significantly lower for sunitinib than pazopanib before imputation ($36,638.96 [$25,199.38] vs. $45,219.75 [$34,828.70] , p= 0.021) and after imputation ($36.393.90 [$26,543.89] vs. $45,652.99 [$35,226.83] , p= 0.015. The RCC-related prescription costs were NS different between the two drugs before and after imputation. CONCLUSIONS: Treatment patterns and persistence with sunitinib or pazopanib were NS different. Sunitinib daily cost was NS different from pazopanib after imputation. Further analysis is needed regarding dosing schedule, days supply, and related calculations. Laboratories, Braintree, MA, USA, 2 Analysis Group, Inc., Boston, MA, USA, 3 Boston Medical Center, Boston University School of Medicine, Boston, MA, USA OBJECTIVES: The study aimed to (1) develop a cost model for colonoscopy preparation among patients referred for colonoscopy using split-dose reduced-volume oral sulfate solution (OSS) and generic polyethylene glycol with electrolytes solution (PEG-ELS), (2) examine cost-savings associated with OSS versus PEG-ELS, and (3) assess the robustness of the cost model. METHODS: Clinical efficacy of each agent was based on the results of a 541-patient clinical trial comparing OSS to PEG-ELS. Cleansing agent and colonoscopy procedure costs were calculated from OptumHealth Reporting & Insights claims data for 2010-Q12013. In the cost model, patients' colonoscopies were tracked until the patient reached age 75. The difference per patient per year (PPPY) in total cleansing agent and colonoscopy procedure costs over the time horizon between the OSS and PEG-ELS cohort was calculated. One-way sensitivity analyses were also conducted to test the robustness of the cost model. RESULTS: The cost model showed that OSS patients had fewer colonoscopies over the time horizon (OSS: 0.158 vs. PEG-ELS: 0.170 PPPY). Total PPPY costs were $280.34 for the OSS cohort and $296.36 for the PEG-ELS cohort, resulting in a cost-saving of $16.01 to the payer for the OSS cohort. Varying the annual colonoscopy completion rate, surveillance intervals, time horizon, and proportion of high risk patients did not change the observation of cost-savings under OSS. Cost-savings switched from the OSS to the PEG-ELS cohort in three cases: (1) base-case cost of a completed colonoscopy decreased by 75%, (2) basecase cost of OSS increased to over $143 per usage, and (3) all non-completers were lost to follow up. CONCLUSIONS: From a payer's perspective, the cost model showed that the use of OSS as the cleansing agent resulted in potential costsavings compared with PEG-ELS. The cost model was robust and cost-savings under OSS remained under various sensitivity analyses.
PCN47 healThCare resoUrCe UTilizaTioN aNd mediCal Care CosT assoCiaTed WiTh NeW Bio-sUrgiCal hemosTasis iN ChiNa
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The CosTs of CaNCer-relaTed aBseNTeeism: a sysTemaTiC revieW of The liTeraTUre Yu J. S. 1 , Seal B. 2 , Carlson J. J. 1 1 University of Washington, Seattle, WA, USA, 2 Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA OBJECTIVES: Cancer-related morbidity and mortality have dramatic impacts on patients and society. Most studies on the economic burden of cancer have focused on the direct costs attributed to healthcare expenditures or the indirect costs due to premature mortality. Cancer's impact on absenteeism has been less well studied. The objective of this review was to summarize and characterize the literature on the economic impact of cancer-related absenteeism. METHODS: We searched PubMed for articles related to the costs of cancer-related absenteeism, which we defined as any type of workplace absence. Additional eligibility criteria included the evaluation of costs per patient and the presentation of absenteeism endpoints in monetary terms. Studies were characterized according to cancer type, healthcare setting (U.S., EU, Asia), valuation approaches, study time period, absenteeism endpoints, and cost results. All costs were adjusted to 2013 dollars or Euros using consumer price indexes and exchange rate data. RESULTS: We found 16 articles that met our inclusion criteria. Seven cancer or pre-cancer types were studied, with breast cancer (7 studies) and colorectal cancer (3 studies) being the most common. Absenteeism endpoints used by study authors varied considerably and included terms such as "absenteeism" (the actual term), "sick leave," "short-term disability," and "permanent disability (reduced hours or workforce departure)." For U.S. studies, total annual absenteeism costs per patient ranged from $3,235 (precancerous cervical lesions) to $59,241 (colorectal cancer). For European studies, total mean absenteeism costs per patient based on time until retirement age of 65 ranged from € 54,216 (breast cancer) to € 129,977 (colorectal cancer). Overall, colorectal cancer was associated with the highest absenteeism costs. CONCLUSIONS: Based on the literature, it is apparent that cancer-related absenteeism poses a significant economic burden to patients, employers, and society. Additional research is required to better understand the absenteeism costs of various types of cancer and to make more accurate comparisons between them.
PCN45 CosT ComParisoN of firsT liNe meTasTaTiC reNal Cell CarCiNoma TreaTmeNTs UsiNg a reTrosPeCTive Claims daTaseT
